Anti-Vascular Endothelial Growth Factor Options and Questions for Diabetic Eye Disease Treatment

Affiliations

Adam R Glassman. JAMA Ophthalmol. 2025.

. 2025 Apr 1;143(4):336-337.

doi: 10.1001/jamaophthalmol.2025.0007.

No abstract available

Comment in

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.
Pieramici DJ, Awh CC, Chang M, Emanuelli A, Holekamp NM, Hu AY, Suñer IJ, Wykoff CC, Brittain C, Howard D, Quezada-Ruiz C, Santhanakrishnan A, Latkany P. Pieramici DJ, et al. JAMA Ophthalmol. 2025 Apr 1;143(4):317-325. doi: 10.1001/jamaophthalmol.2025.0001. JAMA Ophthalmol. 2025. PMID: 40048178 Free PMC article. Clinical Trial.
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.
Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V. Khanani AM, et al. JAMA Ophthalmol. 2025 Apr 1;143(4):326-335. doi: 10.1001/jamaophthalmol.2025.0006. JAMA Ophthalmol. 2025. PMID: 40048197 Free PMC article. Clinical Trial.